About RAPT Therapeutics (RAPT)

RAPT Therapeutics Inc. (RAPT) is a clinical-stage immunology-based biopharmaceutical company that focuses on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company's lead product candidate, FLX475, is an orally available small molecule CCR4 antagonist that is designed to selectively block the migration of activated regulatory T cells into inflamed tissues. This mechanism of action has the potential to treat immune-inflammatory diseases such as psoriasis, inflammatory bowel disease, and rheumatoid arthritis. RAPT is currently conducting a phase 1 clinical trial for FLX475 in healthy volunteers to evaluate its safety, tolerability, and pharmacokinetics.

In addition to FLX475, RAPT has a diverse pipeline of small molecule candidates targeting other immune cell types and pathways. One such candidate is RPT8056, a potentially first-in-class orally available small molecule that selectively inhibits the migration and function of CCR8-expressing T cells and eosinophils. This drug candidate has shown promising preclinical data in models of fibrosis, asthma, and certain types of cancer. RAPT is also developing RPT193, a potent and selective inhibitor of the CCR4 receptor, which has shown potential in the treatment of solid tumors and hematologic malignancies.